Neurocrine (NBIX) Biosciences announced the presentation of new one-year data from the CAHtalyst Adult study of Crenessity showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently announced CAHtalyst Pediatric one-year results and were presented at the Endocrine Society’s Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco. “Results from the pivotal CAHtalyst clinical trial program continue to reinforce the critical role of Crenessity in the management of classic congenital adrenal hyperplasia,” said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. “These one-year data show the lasting ability of Crenessity to effectively manage the ACTH and adrenal steroid imbalances in adults while allowing for lower, more physiologic steroid dosing and improved clinical outcomes.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ Phase 2 Study on NBI-1117568 for Schizophrenia: Key Updates
- Strong Sales Growth and Market Dynamics Justify Buy Rating for Neurocrine
- Neurocrine Biosciences Completes Phase 3 Study on Valbenazine for Schizophrenia
- Neurocrine initiated with a Buy at Goldman Sachs
- Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted Valuation